Fortress Biotech Inc ( (FBIO) ) has released its Q2 earnings. Here is a breakdown of the information Fortress Biotech Inc presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Journey Medical Corporation, a commercial-stage pharmaceutical company based in Scottsdale, Arizona, focuses on selling and marketing FDA-approved prescription products for dermatological conditions. The company is known for its efficient sales and marketing model and currently markets eight branded prescription drugs.
In its second quarter of 2025, Journey Medical reported revenues of $15 million, with Emrosi™ contributing $2.8 million in its first full quarter on the market. The company has recently joined the Russell 2000® and Russell 3000® Indexes, reflecting its growing market presence.
Key financial highlights for the quarter include a gross margin increase to 67% from 61% in the previous year, driven by a favorable product sales mix. However, the company reported a net loss of $3.8 million, slightly higher than the $3.4 million loss in the same quarter of 2024. The increase in selling, general, and administrative expenses to $11.9 million was primarily due to the launch and commercialization of Emrosi.
Journey Medical’s recent corporate developments include expanded payer access for Emrosi, now covering over 100 million commercial lives in the U.S., and the presentation of positive Phase 3 trial data at a dermatology conference. The company also appointed a new Chief Operating Officer, Ramsey Alloush, in April 2025.
Looking ahead, Journey Medical’s management remains optimistic about the company’s growth prospects, emphasizing the strong market traction of Emrosi and the potential for continued operating leverage in the latter half of 2025 and beyond.